Showing 1 - 9 results of 9 for search 'Nahad Sedaghat', query time: 0.03s Refine Results
  1. 1
    Endoscopic clipping of a complicated esophageal perforation following pneumatic dilation for achalasia: A case study and literature review

    Endoscopic clipping of a complicated esophageal perforation following pneumatic dilation for achalasia: A case study and literature review by Mohammad Minakari, Nahad Sedaghat

    Published 2022-11-01
    Get full text
    Article
  2. 2
    Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity

    Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety an... by Nahad Sedaghat, Nahad Sedaghat, Masoud Etemadifar, Noushin Lotfi, Farnaz Sayahi, Ahmad Chitsaz, Mehri Salari, Alireza Ghasemi Movaghar

    Published 2023-02-01
    Get full text
    Article
  3. 3
    Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model

    Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model by Niloofar Najarzadegan, Mahboobeh Madani, Masoud Etemadifar, Nahad Sedaghat

    Published 2022-01-01
    Get full text
    Article
  4. 4
    Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model.

    Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model. by Niloofar Najarzadegan, Mahboobeh Madani, Masoud Etemadifar, Nahad Sedaghat

    Published 2022-01-01
    Get full text
    Article
  5. 5
    Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse

    Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acut... by Masoud Etemadifar, Hosein Nouri, Mehri Salari, Nahad Sedaghat

    Published 2022-01-01
    Get full text
    Article
  6. 6
    Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient

    Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient by Masoud Etemadifar, Amirhossein Akhavan Sigari, Nahad Sedaghat, Mehri Salari, Hosein Nouri

    Published 2021-10-01
    Get full text
    Article
  7. 7
    Multiple sclerosis in sarcoidosis patients: Two case reports

    Multiple sclerosis in sarcoidosis patients: Two case reports by Masoud Etemadifar, Armin Mehri, Nahad Sedaghat, Mehri Salari, Parsa Tavassoli Naini

    Published 2022-09-01
    Get full text
    Article
  8. 8
    Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies

    Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies by Masoud Etemadifar, Ramin Sami, Mehri Salari, Nahad Sedaghat, Amirhossein Akhavan Sigari, Ali Aghababaei, Mohammadreza Najafi, Donya Sheibani Tehrani

    Published 2021-01-01
    Get full text
    Article
  9. 9
    Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis

    Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis by Masoud Etemadifar, Amir Parsa Abhari, Hosein Nouri, Amirhossein Akhavan Sigari, Seyed Mohammad Piran Daliyeh, Mohammad Reza Maracy, Mehri Salari, Shiva Maleki, Nahad Sedaghat

    Published 2022-01-01
    Get full text
    Article

Search Tools: